Past Global Symposia

23rd January 2026

TIME	PROGRAMME
08.00 – 08.05	WELCOME Robin Gore
08.05 – 09.05	Japanese Society of Allergology Chaired by: George Gkimpas
08.05 – 08.20	Allergen immunotherapy in asthma Discover how allergen immunotherapy, including SCIT and SLIT, can improve asthma control, modify disease, and offer long-term prevention in allergic conditions worldwide. Kazuyuki Nakagome
08.20 – 08.35	Advances in the diagnosis and treatment of Stevens–Johnson syndrome/toxic epidermal necrolysis Explore advances in diagnosing and treating SJS/TEN, including cancer drug reactions with similar features. Gain practical guidance and support global efforts to standardise care. Yuko Watanabe
08.35 – 08.50	Japanese guidelines for atopic dermatitis Sharing the Japanese guidelines for atopic dermatitis to highlight evidence-based treatment strategies and promote shared decision-making between physicians and patients, respecting individual values and preferences. Hidehisa Saeki
08.50 – 09.05	Panel Q&A
09:05 – 09:20	BREAK
09.20 – 10.20	Industry Symposium – Non-accredited For more information see the Sponsored Symposia page
10.20 – 11.20	Chaired by: Claudia Gore
10.20 – 10.35	Lessons learned on the standardisation of oral food challenges A practical session on oral food challenges, detailing how and when to perform them and how to avoid pitfalls in diagnosing and following up food allergy. Philippe Eigenmann
10.35 – 10.50	EAACI’s Strategic Vision: Artificial Intelligence as a Transformative Force in Allergic Disease Management – Clinical Applications and Mechanistic Insights Explore how AI can transform global allergy care by improving diagnosis, personalizing treatment, and expanding equitable access to specialist-level expertise in alignment with EAACI’s evidence-based vision for clinical implementation. Mo Shamji
10.50 – 11.05	EAACI strategy for the precise management of antibiotic allergy and its impact on EU antibiotic resistance The talk emphasises improving beta-lactam allergy diagnosis and de-labelling false cases to reduce antibiotic resistance and enhance global health outcomes. Maria Torres
11.05 – 11.20	Panel Q&A
11.20 – 11.40	BREAK
11.40 – 13.00	Presidents’ Forum This is the only worldwide platform where presidents of 5 global societies meet to discuss topics of interest in the field of allergic disease. It provides an opportunity to ask questions to the presidents Live meeting of the Presidents of the Partner Societies Chaired by: Adnan Custovic Speakers: For AAAAI: Dr Frank S. Virant For EAACI: Professor Maria Torres For WAO: Professor Mario Morais Almeida For JSA: Dr Motohiro Ebisawa For BSACI: Dr Robin Gore
13.00 – 13.40	BREAK
13.40 – 14.40	Industry Symposium – Non-accredited For more information see the Sponsored Symposia page
14.40 – 15.40	Chaired by: Stephen Durham
14.40 – 14.55	Allergy Psychology interactive cases Explore how the mind shapes allergic reactions and learn about the link between immunology and psychology to deliver new treatment approaches that address both the physical and mental aspects of allergy. Christina Jones
14.55 – 15.10	Atopic Dermatitis interactive cases Presentation of a challenging adolescent atopic dermatitis case, highlighting therapeutic decision-making using latest guidelines, network meta-analyses, treat-to-target strategies, and immunological targets of emerging systemic therapies. Carsten Flohr
15.10 – 15.25	Venom allergy interactive cases From stings to systemic reactions – understand and manage hymenoptera venom allergy with confidence. Pamela Ewan
15.25 – 15.40	Panel Q&A
15.40 – 15.55	BREAK
15.55 – 16.55	Chaired by: Shuaib Nasser
15.55 – 16.10	Food Protein-Induced Enterocolitis Syndrome (FPIES): Current Status and Future Directions Learn how to recognise, diagnose, and manage FPIES, and explore emerging research shaping safer food introduction and improved clinical care. Carina Venter
16.10 – 16.25	Pollen-Food Allergy Syndrome: Consensus on Management Explore the rising global prevalence of Pollen-Food Allergy Syndrome, its diverse presentations, potential environmental and dietary causes, and the current challenges in achieving consistent international diagnosis and management guidelines. Amanda Cox
16.25 – 16.40	Omalizumab Treatment of Food Allergy Understand the risks, benefits, and real-world impact of biologics in allergy care Aikaterini Anagnostou
16.40 – 16.55	Panel Q&A
16.55 – 17.10	BREAK
17.10 – 18.10	Chaired by: Olympia Tsilochristou
17.10 – 17.25	DRESS syndrome: A literature review and treatment algorithm DRESS syndrome is a rare, serious drug-induced hypersensitivity reaction with up to 10% mortality. It affects multiple organs and often presents 2–8 weeks after drug exposure, delaying diagnosis. This session explores the nuances of DRESS syndrome treatment. Luz Fonacier
17.25 – 17.40	DRACMA’ guideline update 2024 – Milk supplement/replacement formulas for infants and toddlers with CMA A session exploring milk protein allergy in infancy, its persistence and severity, and the importance of a reasoned substitute choice when breastfeeding is not available. Alessandro Fiocchi
17.40 – 17.55	Standards for intravenous Rapid Drug Desensitisation Explore standardised intravenous rapid drug desensitisation protocols to harmonise practice, enhance patient safety, and equip clinicians with the knowledge and confidence to safely manage high-risk allergic patients worldwide. Ricardo Madrigal
17.55 – 18.10	Panel Q&A
18.10 – 18.15	CLOSING AND PRESIDENT’S REMARKS

31st January 2025

TIME	PROGRAMME
08.00 – 08.05	WELCOME
	Chairs: Bryan Martin & George Gkimpas
08.05 – 08.20	Updated grading system for systemic allergic reactions A review looking at a unified grading scale for systemic allergic reactions due to allergen immunotherapy which can be applied across research and clinical practice. Paul Turner
08.20 – 08.35	Penicillin delabeling Pathways Learn about initiatives to remove false penicillin allergy labels in an effort to reduce antimicrobial resistance which is one of the greatest threats to global health. Lene Garvey
08.35 – 08.50	Chronic cough: An allergy and ENT perspective This talk discusses the aetiology of chronic cough including hypersensitivity of the cough reflex. Promising treatments on offer include ATP receptor antagonists. Philip Rouadi
08.50 – 09.05	Panel Q&A
09:05 – 09:20	BREAK
09.20 – 10.20	COMPANY SYMPOSIUM
	Chairs: Mohammed Shamji & Claudia Gore
10.20 – 10.35	Management of hereditary angioedema The management of Hereditary Angioedema has significantly advanced over the past two decades. Hear about the modern theapies available worldwide to improve disease control and quality of life. Maria Teresa Cabellero
10.35 – 10.50	Highlights from the AACI/ENDA position paper on drug provocation testing In drug hypersensitivity, drug provocation testing (DPT) is the gold standard for diagnosis. This position paper provides guidelines for optimizing DPT use, ensuring safety while maximizing available resources, and avoiding unnecessary procedures. Annick Barbaud
10.50 – 11.05	Nutritional and dietary interventions in children with atopic dermatitis without food allergy This session focuses on how nutrition may improve atopic dermatitis, without necessarily avoiding food allergens. Carina Venter
11.05 – 11.20	Panel Q&A
11.20 – 11.40	BREAK
11.40 – 13.00	Presidents’ Forum This is the only worldwide platform where presidents of 5 global societies meet to discuss topics of interest in the field of allergic disease. It provides an oppurtunity to ask questions to the presidents. Session-linked discussion Chair: Syed Hasan Arshad Speakers: For BSACI: Dr Robin Gore For EAACI: Professor Maria Torres For WAO: Professor Mario Morais Almeida For AAAAI: Professor Paul Williams For ALLSA: Dr Sarah Karabus
13.00 – 14.00	BREAK
	Chairs: Leanne Goh & Graham Roberts
14.00 – 14.20	Challenging food allergy cases Adam Fox presents 2 challenging food allergy case studies prompting us to reflect on how to provide rapid and high quality allergy services. Adam Fox
14.20 – 14.40	A not-so-straightforward referral Learn about the important role allergy nurses provide across the allergic diseases spectrum. Phoebe Moulsdale
14.40 – 15.00	Challenging immunodeficiency cases In this session Andrew Gennery discusses diagnostic and therapeutic dilemmas in managing patients with inborn errors of immunity. Andrew Gennery
15.00 – 15.20	Panel Q&A
15.20 – 15.55	BREAK
	Chair: Nicola Brathwaite
15.55 – 16.10	When it’s not a duck – FPIES masquerading as malnutrition This session presents a case of FPIES masquerading as malnutrition in a sick child. Learn how to recognise unusual presentations of food allergy in developing countries with high burden of infectious diseases. Candice Royal
16.10 – 16.25	Can alpha gal allergy be predicted using IgE levels? In this session Michael Levin reviews alpha-gal allergy presentation, diagnosis and explores the mechanisms of food allergies. Michael Levin
16.25 – 16.40	Unique insights on Severe Cutaneous Allergic Reactions (SCAR) from TB and HIV endemic settings This session discusses immunopathogenesis, genetic risks and novel diagnostic approaches to SCAR in a TB/ HIV endemic setting. Jonny Peter
16.40 – 16.55	Panel Q&A
16.55 – 17.10	BREAK
	Chairs: Christina Jones & Frank Virant
17.10 – 17.25	Anaphylaxis Practice Parameters Highlights A review of anaphylaxis practice parameters including diagnostic criteria in infants, investigating possible HaT or mastocytosis, need for emergency services after AAI use and risk of b-blockers and ACE inhibitors in immunotherapy. David Golden
17.25 – 17.40	Urticaria Practice Parameter highlights Chronic urticaria is common with many emerging phenotypes/ endotypes. Jonathan Bernstein reviews diagnosis, treatment and monitoring of chronic urticaria to ensure optimal outcomes. Jonathan Bernstein
17.40 – 17.55	Immunotherapy Practice Parameter highlights In this session Anne Ellis will share updates on new developments in the Immunotherapy Practice Parameters from the Immunotherapy working group. Anne Ellis
17.55 – 18.10	Panel Q&A
18.10 – 18.15	CLOSING AND PRESIDENTS’ REMARKS

31st January 2024

TIME	PROGRAMME
09:00 – 09:05	WELCOME
09:05 – 10:30	WAO SESSION – IMMUNOTHERAPY Chairs: For WAO: Prof Bryan Martin, Ohio State University Columbus, USA For BSACI: Dr George Gkimpas, Royal Preston Hospital, UK
09.05 – 09.20	Personalized medicine in immunotherapy AIT is a paradigmatic example of Disease Modyfing Treatment and of Personalized Medicine. The Molecular Allergy Diagnosis (or Component Diagnosis or PAMD@) is a clear added value in defining the true sensitization in allergic patients and the possibility of shared decision with patients about SCIT. Giorgio Walter Canonica, Humanitas Research Hospital, Italy
09.20 – 09.35	Immunotherapy and component testing: potential role in the future The first premise for the prescription of immunotherapy based on PAMD@ is the assessment of IgE positivity to genuine versus cross-reactive allergens. Allergen immunotherapy should be prescribed to patients with demonstrated IgE-mediated sensitivity to relevant allergens that induce clinical manifestations. Ignacio J. Ansotegui, Hospital Quironsalud Bizkaia, Spain
09.35 – 09.50	Oral Immunotherapy: A shared-decision discussion Two clinicians will discuss 5 key questions most allergists and patients are asking about OIT. Practical advice on how to have an informative and effective shared-decision making conversation with a patient who is considering oral immunotherapy. Dana Wallace, Nova Southeastern University College of Allopathic Medicine Fort Lauderdale, USA John Oppenheimer, Clin professor of Medicine, UMDNJ-Rutgers, USA
09.50 – 10.05	Using immunotherapy to prevent the atopic march. Mário Morais-Almeida, CUF – Hospitais e Clínicas, Portugal
10.05 – 10.30	Panel Q&A
10:30 – 10:45	BREAK
10:45 – 12:10	EAACI UPDATE Chairs: For EAACI: Dr Maria Torres, University of Malaga and Malaga Regional University Hospital, Spain For BSACI: Dr Mo Shamji, Imperial College, UK
10.45 – 11.00	New nomenclature on allergic diseases. From Bench to bedside The cultural change brought by the new nomenclature will lead to novel concepts of diagnostic tools, improving therapies, and disease management and will guide future research into more innovative strategies for patient care. Marek Jutel, Wroclaw Medical University, Poland
11.00 – 11.15	EAACI Guidelines on the diagnosis and management of IgE-mediated food allergy This talk will provide clear and practical recommendations to be applied in clinical practice in order to improve the accuracy of food allergy diagnosis around the world. Alexandra F. Santos, King’s College London, UK
11.15 – 11.30	Allergy to stings and bites from non-Hymenoptera insects: available diagnostics and treatment Allergy to rare or locally important arthropods is not well known. The key is to be aware of rare arthropods and learn how to diagnose and treat allergy. Gunter Sturm, Medical University of Graz, Austria
11.30 – 11.45	Severe asthma in real life. The EARL initiative The EAACI EARL program is working on integrating Real-World evidence and EBM in health guidelines, since a defined method about how to integrate RWE in guidelines is still missing. Delegates will learn the value of RWE and the proposal to create guidelines on the correct methodology to handle data coming from randomized, non-randomized studies and from registries. Stefano Del Giacco, University of Cagliari, Italy
11.45 – 12.10	Panel Q&A
12.10 – 12.40	BREAK
12.40 – 13.50	Presidents’ Forum The presidents of the partner Societies will revisit the allergy state-of-the-art Chair: For BSACI: Dr Glenis Scadding, Royal National ENT Hospital and University College, UK Speakers: For BSACI: Prof Graham Roberts, University of Southampton, UK For EAACI: Prof Stefano Del Giacco, University of Cagliari, Italy For WAO: Prof Bryan Martin, Ohio State University Columbus, USA For AAAAI: Prof Jonathan Bernstein, University of Cincinnati College of Medicine, Bernstein Allergy group and Bernstein Clinical Research Center, USA
13.50 – 14.10	BREAK
14:10 – 15.35	BSACI SESSION – CHALLENGING INTERACTIVE CASES Chairs: Dr Shuaib Nasser, Cambridge University Hospitals NHS Foundation Trust, UK Dr Matt Doyle, Jersey Allergy Clinic, Jersey, Channel Islands
14.10 – 14.25	Food allergy cases Composite dishes often make it difficult to track down the allergen responsible for food allergic reactions. It is key to take a detailed history of exactly what was in the dish that provoked symptoms and undertake a food challenge if the history does not match the test results. Isabel Skypala, Guys and St Thomas NHS Foundation Trust & Imperial College, UK
14.25 – 14.40	Perioperative allergy cases Perioperative allergy is a rare but devasting event which can be uniquely challenging to recognise, investigate and diagnose. This session will cover some of the complexities and pitfalls in the end-to-end journey from initial event to eventual diagnosis. Louise Savic, Leeds Teaching Hospitals NHS Trust, UK
14.40 – 14.55	Gastro Allergy cases Multi-system allergic disease is increasing globally. Although many will be aware about the increases in allergy respiratory and dermatological presentations, gastro-intestinal conditions are also seeing a significant rise in prevalence. Edward Gaynor, Great Ormond Street Hospital, UK Leanne Goh, Imperial College Healthcare Trust and Great Ormond Street Hospital, UK
14.55 – 15.10	Immunodeficiency cases This talk highlights presentation of interesting immunodeficiency cases, how they are diagnosed and how to manage these patients. Ariharan Anantharachagan, Lancashire Teaching Hospitals NHS Foundation Trust, UK
15.10 – 15.35	Panel Q&A
15:35 – 15:50	BREAK
15:50 – 16:50	COMPANY SYMPOSIUM DBV Technologies Chairs: Gideon Lack, KHP Institute of Women and Children’s Health at Evelina London, Guy’s & St. Thomas’ NHS Foundation Trust, London, UK Hugh Sampson, Icahn School of Medicine at Mount Sinai, New York, USA Epicutaneous immunotherapy for peanut allergy: from science to clinical practice Gideon Lack, KHP Institute of Women and Children’s Health at Evelina London, Guy’s & St. Thomas’ NHS Foundation Trust, London, UK Hugh Sampson, Icahn School of Medicine at Mount Sinai, New York, USA Stefania Arasi, Bambino Gesù Children Research Hospital (IRCCS), Rome
16.50 – 18:15	AAAAI UPDATE Chairs: For AAAAI: Prof Jonathan Bernstein, University of Cincinnati College of Medicine, Bernstein Allergy group and Bernstein Clinical Research Center, USA For BSACI: Prof Graham Roberts, University of Southampton, UK
16.50 – 17.05	The ACAAI/AAAAI Atopic Dermatitis guidelines The Atopic Dermatitis Guidelines: 2023 AAAAI/ACAAI Joint Task Force (JTF) on Practice Parameters GRADE- and Institute of Medicine-based recommendations will assist clinicians in caring for their patients with atopic dermatitis. Lynda Schneider, Harvard Medical School & Boston Children’s Hospital, USA
17.05 – 17.20	GRADE guidelines for chronic rhinosinusitis with nasal polyps An update of the JTF chronic rhinosinusitis with NP guidelines which is a very common clinical presentation seen by Allergists and Immunologists. This is a GRADE document so the certainty of medical evidence supporting recommendations is provided. This talk could reaffirm or change the way clinicians are currently managing their patients with CRSwNP. Jonathan Bernstein, University of Cincinnati College of Medicine, Bernstein Allergy group and Bernstein Clinical Research Center, USA
17.20 – 17.35	Asthma: What’s new in EPR4 and GINA. Evidence based strategies for the management of asthma in all age groups are available to improve the care of children with asthma around the world. Leonard Bacharier, Vanderbilt University Medical Center, USA
17.35 – 17.50	Drug Allergy: A Practise parameter update The US Joint Task Force recently completed an update to the drug allergy practice parameters. This update was a data-derived and expert consensus document covering key areas of drug allergy. This session will aim to improve the global understanding of the US drug allergy practice parameter approaches to antibiotic allergy assessment and de-labeling. Kimberly Blumenthal, Mass General Brigham, USA
17.50 – 18.15	Panel Q&A
18:15 – 18:20	CLOSING AND PRESIDENTS’ REMARKS

10th February 2023

TIME	PROGRAMME
08:00 – 08:15	WELCOME
08:15 – 09:40	WAO SESSION – DRUG ALLERGY
08:15 – 09:40	Drug Desensitization Ricardo Madrigal-Burgaleta, St Bartholomew’s Hospital, Barts Health NHS Trust, UK MRGPRX2 – future therapeutics for drug allergy Pedro Giavina-Bianchi, Clinical Immunology and Allergy Division of University of São Paulo, Brazil Computer aided early diagnosis of SJS/TEN Riichiro Abe, Niigata Graduate School of Medical and Dental Sciences, Japan Chaired by: WAO representative Pascal Demoly, University hospital of Montpellier, France and BSACI representative Rubaiyat Haque, Guy’s and St Thomas’ NHS Foundation Trust, UK Panel Q+A
09:40 – 10:40	COMPANY SYMPOSIUM
10:40 – 10:50	BREAK
10:50 – 12:15	EAACI SESSION – ENVIRONMENTAL IMPACT ON ALLERGY
10:50 – 12:15	Microbiome for allergy prevention Erika von Mutius, LMU, Germany Climate change and the changing allergen landscape Isabella Pali-Schöll, University of Veterinary Medicine & Medical University of Vienna, Austria Infection and immune interactions in the airways Jürgen Schwarze, University of Edinburgh, UK Panel Q+A Chaired by: EAACI representative Mohamed Shamji, Imperial College London, UK and BSACI representative Glenis Scadding, Royal National ENT Hospital and University College London, UK
12:15 – 12:30	BREAK
12:30 – 13:00	Keynote Lecture CALL to ACTION: Environmental causes of allergic disease and effective interventions – What should we do as an allergy community? Stephen Holgate, University of Southampton, UK
13:00 – 14:15	BREAK
14:15 – 15:40	BSACI SESSION – CHALLENGES IN ALLERGY
14:15 – 15:40	FPIES and EOE in adults Isabel Skypala, Royal Brompton & Harefield Hospitals – part of Guys & St Thomas NHS Foundation Trust, UK Difficult conversations with adolescents and young adults Claudia Gore, Imperial College Healthcare NHS Trust, UK The future of allergy diagnostics Alexandra Santos, King’s College London and Evelina London Children’s Hospital, UK Panel Q+A Chaired by: BSACI representatives Susana Marinho, University of Manchester, UK and Marta Vazquez-Ortiz, Imperial College London, UK
15:40 – 16:40	COMPANY SYMPOSIUM
16:40 – 16:50	BREAK
16:50 – 18:15	AAAAI SESSION – IMMUNOTHERAPY
16:50 – 18:15	Avoidance to remission to cure – how far does immunotherapy take us? Wayne Shreffler, Massachusetts General Hospital / Harvard Medical School, USA Future Adjuvants in Immunotherapy J. Andrew Bird, University of Texas Southwestern Medical Center, USA Conversations with patients about food oral immunotherapy R. Sharon Chinthrajah & Sayantani Sindher, Stanford University, USA Panel Q+A Chaired by: AAAAI representative Brian P. Vickery, Emory University and Children’s Healthcare of Atlanta, USA and BSACI representative Stephen Durham, Imperial College London and Royal Brompton Hospital London, UK
18:15 – 18:30	CLOSING AND PRESIDENTS’ REMARKS